https://www.selleckchem.com/pr....oducts/sb-204990.htm
All patients in both groups will receive antiplatelet agents and high-intensity statins, including 20 mg rosuvastatin or 40-80 mg atorvastatin or at the maximum tolerated dose. All of them will undergo MRI at recruitment and after 26 weeks. The primary outcomes are changes in intracranial atherosclerotic plaques in the MRI before and after 6 months treatment. This trial is being conducted at Chang Gung Memorial Hospital at Chiayi, Taiwan. This trial has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (a
Like
Comment
Share
